(Lung Cancer) Trastuzumab Deruxtecan Monotherapy: DESTINY-Lung01 Results
(Lung Cancer) Trastuzumab Deruxtecan Monotherapy: DESTINY-Lung01 Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Trastuzumab Deruxtecan Monotherapy: DESTINY-Lung01 Results
- June 19, 2020
- 2 min read
From May 29 to 31, 2020, Egbert F. Smit presented at the ASCO 2020 Virtual Meeting the results on the efficacy and safety of anti-HER2 antibody drug anti-HER2 antibody-drug conjugate monotherapy in HER2-positive metastatic non-small cell lung cancer patients from the DESTINY-Lung01 Phase II clinical trial.
The DESTINY-Lung01 Phase II clinical trial administered anti-HER2 antibody-drug conjugate monotherapy at 6.4mg/kg in 3-week cycles to HER2-positive metastatic non-small cell lung cancer patients. The primary endpoint was objective response rate, with secondary endpoints including duration of response, progression-free survival, and safety.
Patient characteristics in this trial (42 patients) were as follows: female 64.3%, median age 63.0 years, under 65 years old 59.5%, patients with central nervous system metastases 45.2%, ECOG score 0 at 23.8%, ECOG score 1 at 76.2%, median number of prior treatments was 2, and prior medication history included: platinum-based agents 54.8%, anti-PD-1/PD-L1 antibody drugs 54.8%.
At the data cutoff in November 2019 (median treatment duration 7.75 months), the results were as follows: primary endpoint objective response rate was 61.9%, secondary endpoints showed median duration of response not yet reached, median progression-free survival of 14.0 months, and disease control rate of 90.5%.
Regarding safety, the overall adverse event rate was 100%, grade 3 or higher adverse event rate was 64.3%, treatment interruption rate due to adverse events was 59.5%, dose reduction rate was 38.1%, treatment discontinuation rate was 23.8%, and interstitial lung disease was 11.9% (N=5 patients).
Based on the DESTINY-Lung01 trial results, Egbert F. Smit concluded that anti-HER2 antibody drug anti-HER2 antibody-drug conjugate monotherapy demonstrated a high objective response rate in HER2-positive metastatic non-small cell lung cancer patients, with adverse events consistent with those observed in other clinical trials.
[Disclaimer] The clinical trial data and pharmaceutical information from overseas trials translated by "Medical Supporter" are not intended to encourage participation in clinical trials or the use of any new drugs. The translated materials are for reference only and do not constitute medication guidelines. Please consult with your healthcare professionals, and refer to the original text below for accurate content.
Source: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. (2020 ASCO Virtual Scientific Program, Abstract No: 9504)
-
Investigational drugs
(Lung Cancer) Topotecan and Topotecan + Berzosertib Phase II clinical trial results. (Lung Cancer) Is anti-HER2 antibody-drug conjugate effective for HER2-mutant non-small cell lung cancer? (Lung Cancer) Is anti-B7-H3 antibody drug DS-7300 effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.